Answers are grounded in this paper and cite their sources.
Background: Non-alcoholic fatty liver disease (NAFLD) refers to abnormal fat build-up in the liver. Left unaddressed, this condition can silently worsen into fibrosis and serious long-term liver damage. From an Ayurvedic view, this closely resembles Yakritodar, rooted in metabolic imbalances like Agnimandya and Medo Dushti. No approved conventional drug exists for NAFLD, making Ayurvedic alternatives clinically relevant. Clinical Findings: A 39-year-old male patient came to us with a six-month history of right-sided upper abdominal pain, bloating after meals, breathlessness, poor digestion, loss of appetite, and persistent fatigue. He had also been experiencing mild difficulty urinating at night for the past eight months. Abdominal ultrasonography confirmed Grade II fatty liver with hepatomegaly and incidentally revealed a prostatic calcification of 0.61 cm. Blood tests showed raised SGPT levels and dearranged lipid profile. Intervention: A polyherbal formulation containing Palash Kshar (125 mg) and Katuki Churna (375 mg) in 500 mg capsule form was administered at a dose of two capsules twice daily after food with lukewarm water, along with structured dietary and lifestyle modification for three months (09/01/2025–09/04/2025). Outcome: Post-treatment assessment demonstrated a reduction in SGPT levels (55 U/L to 36 U/L), improvement in lipid parameters, a decrease in liver size (16.71 cm to 14.50 cm), regression from Grade II to Grade I fatty liver, and a weight reduction of 8 kg (77 kg to 69 kg). Notably, complete resolution of incidental prostatic calcification was observed on follow-up ultrasonography. No adverse effects were reported. Conclusion: The combined use of Palash Kshar and Katuki Churna, along with lifestyle modification, showed significant clinical, biochemical and radiological improvement in NAFLD (Yakritodar), with incidental resolution of prostatic calcification. The findings suggest the therapeutic potential and safety of Ayurvedic interventions in metabolic liver disorders.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: